Thrombospondins in the transition from myocardial infarction to heart failure

Journal of Molecular and Cellular Cardiology

Volumn 90, Issue , 2016, Pages 102-110

  Kirk, Jonathan A ^a   Cingolani, Oscar H ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Heart failure; Myocardial infarction; Remodeling; TGF ; Thrombospondin

Indexed keywords

CHEMOKINE; CYTOKINE; MATRIX METALLOPROTEINASE; PROTEIN ADAMTS 7; THROMBOSPONDIN; THROMBOSPONDIN 1; THROMBOSPONDIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; EXTRACELLULAR MATRIX; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; INTRACELLULAR SIGNALING; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; ANIMAL; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; ENDOMYOCARDIAL FIBROSIS; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION; THROMBOSPONDINS;

EID: 84951142503     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.12.009     Document Type: Review

References (118)

1. Parikh N.I., Gona P., Larson M.G., Fox C.S., Benjamin E.J., Murabito J.M., et al. Long-term trends in myocardial infarction incidence and case fatality in the national heart, lung, and blood institute's framingham heart study. Circulation 2009, 119:1203-1210.
2. Mozaffarian D., Benjamin E.J., Go A.S., Arnett D.K., Blaha M.J., Cushman M., et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015, 131:e29-322.
3. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J. Cell Biol. 1995, 130:503-506.
4. Bradshaw A.D. Macrophage expression of secreted protein acidic and rich in cysteine (SPARC): implications for cardiac repair and fibrosis. J. Mol. Cell. Cardiol. 2015, (in press, JMCC9593).
5. Frangogiannis N.G. Matricellular proteins in cardiac adaptation and disease. Physiol. Rev. 2012, 92:635-688.
6. Lawler J., Duquette M., Whittaker C.A., Adams J.C., McHenry K., DeSimone D.W. Identification and characterization of thrombospondin-4, a new member of the thrombospondin gene family. J. Cell Biol. 1993, 120:1059-1067.
7. Lawler J., Hynes R.O. The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J. Cell Biol. 1986, 103:1635-1648.
8. Adams J.C., Lawler J. The thrombospondins. Cold Spring Harb. Perspect. Biol. 2011, 3:a009712.
9. Adams J.C. Thrombospondins: multifunctional regulators of cell interactions. Annu. Rev. Cell Dev. Biol. 2001, 17:25-51.
10. Hartupee J., Mann D.L. Role of inflammatory cells in fibroblast activation. J. Mol. Cell. Cardiol. 2015, (in press, JMC9594).
11. Turner N.A. Inflammatory and fibrotic responses of cardiac fibroblasts to myocardial damage associated molecular patterns (DAMPs). J. Mol. Cell. Cardiol. 2015, (in press, JMC9542).
12. Frangogiannis N.G. Regulation of the inflammatory response in cardiac repair. Circ. Res. 2012, 110:159-173.
13. Kempf T., Zarbock A., Widera C., Butz S., Stadtmann A., Rossaint J., et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat. Med. 2011, 17:581-588.
14. Wehrens X.H., Doevendans P.A. Cardiac rupture complicating myocardial infarction. Int. J. Cardiol. 2004, 95:285-292.
15. Sezaki S., Hirohata S., Iwabu A., Nakamura K., Toeda K., Miyoshi T., et al. Thrombospondin-1 is induced in rat myocardial infarction and its induction is accelerated by ischemia/reperfusion. Exp. Biol. Med. (Maywood) 2005, 230:621-630.
16. Frangogiannis N.G., Ren G., Dewald O., Zymek P., Haudek S., Koerting A., et al. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation 2005, 111:2935-2942.
17. Bujak M., Frangogiannis N.G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc. Res. 2007, 74:184-195.
18. Murphy-Ullrich J.E., Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 2000, 11:59-69.
19. Crawford S.E., Stellmach V., Murphy-Ullrich J.E., Ribeiro S.M., Lawler J., Hynes R.O., et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998, 93:1159-1170.
20. Zhou Y., Poczatek M.H., Berecek K.H., Murphy-Ullrich J.E. Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Biochem. Biophys. Res. Commun. 2006, 339:633-641.
21. Chatila K., Ren G., Xia Y., Huebener P., Bujak M., Frangogiannis N.G. The role of the thrombospondins in healing myocardial infarcts. Cardiovasc. Hematol. Agents Med. Chem. 2007, 5:21-27.
22. Lopez-Dee Z., Pidcock K., Gutierrez L.S. Thrombospondin-1: multiple paths to inflammation. Mediat. Inflamm. 2011, 2011:296069.
23. Ortiz-Masia D., Diez I., Calatayud S., Hernandez C., Cosin-Roger J., Hinojosa J., et al. Induction of CD36 and thrombospondin-1 in macrophages by hypoxia-inducible factor 1 and its relevance in the inflammatory process. PLoS One 2012, 7.
24. Lamy L., Foussat A., Brown E.J., Bornstein P., Ticchioni M., Bernard A. Interactions between CD47 and thrombospondin reduce inflammation. J. Immunol. 2007, 178:5930-5939.
25. Papageorgiou A.P., Swinnen M., Vanhoutte D., VandenDriessche T., Chuah M., Lindner D., et al. Thrombospondin-2 prevents cardiac injury and dysfunction in viral myocarditis through the activation of regulatory T-cells. Cardiovasc. Res. 2012, 94:115-124.
26. - T cells in response to inflammation. J. Immunol. 2006, 177:3534-3541.
27. Liu Z., Morgan S., Ren J., Wang Q., Annis D.S., Mosher D.F., et al. Thrombospondin-1 (TSP1) contributes to the development of vascular inflammation by regulating monocytic cell motility in mouse models of abdominal aortic aneurysm. Circ. Res. 2015, 117:129-141.
28. Agah A., Kyriakides T.R., Lawler J., Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am. J. Pathol. 2002, 161:831-839.
29. Frolova E.G., Sopko N., Blech L., Popovic Z.B., Li J., Vasanji A., et al. Thrombospondin-4 regulates fibrosis and remodeling of the myocardium in response to pressure overload. FASEB J. 2012, 26:2363-2373.
30. Frolova E.G., Pluskota E., Krukovets I., Burke T., Drumm C., Smith J.D., et al. Thrombospondin-4 regulates vascular inflammation and atherogenesis. Circ. Res. 2010, 107:1313-1325.
31. Whittaker P., Boughner D.R., Kloner R.A. Role of collagen in acute myocardial infarct expansion. Circulation 1991, 84:2123-2134.
32. Nian M., Lee P., Khaper N., Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res. 2004, 94:1543-1553.
33. Sun Y., Kiani M.F., Postlethwaite A.E., Weber K.T. Infarct scar as living tissue. Basic Res. Cardiol. 2002, 97:343-347.
34. Lindsey M.L., Gannon J., Aikawa M., Schoen F.J., Rabkin E., Lopresti-Morrow L., et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 2002, 105:753-758.
35. Zamilpa R., Lindsey M.L. Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. J. Mol. Cell. Cardiol. 2010, 48:558-563.
36. Lindsey M.L., Iyer R.P., Jung M., DeLeon-Pennell K.Y., Ma Y. Matrix metalloproteinases as input and output signals for post-myocardial infarction remodeling. J. Mol. Cell. Cardiol. 2015, (in press, JMC9601).
37. Booz G.W., Baker K.M. Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc. Res. 1995, 30:537-543.
38. Cleutjens J., Huynen F., Smits J., Bornstein P., Daemen M. Thrombospondin-2 deficiency in mice results in cardiac rupture early after myocardial infarction (abstract). Circ. Res. 1999, 100.
39. Schellings M.W., Pinto Y.M., Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc. Res. 2004, 64:24-31.
40. Schroen B., Heymans S., Sharma U., Blankesteijn W.M., Pokharel S., Cleutjens J.P., et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ. Res. 2004, 95:515-522.
41. Reinecke H., Robey T.E., Mignone J.L., Muskheli V., Bornstein P., Murry C.E. Lack of thrombospondin-2 reduces fibrosis and increases vascularity around cardiac cell grafts. Cardiovasc. Pathol. 2013, 22:91-95.
42. Vanhoutte D., van Almen G.C., Van Aelst L.N., Van Cleemput J., Droogne W., Jin Y., et al. Matricellular proteins and matrix metalloproteinases mark the inflammatory and fibrotic response in human cardiac allograft rejection. Eur. Heart J. 2013, 34:1930-1941.
43. Ma Y., de Castro Bras L.E., Toba H., Iyer R.P., Hall M.E., Winniford M.D., et al. Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflugers Arch. 2014, 466:1113-1127.
44. Desmouliere A., Geinoz A., Gabbiani F., Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 1993, 122:103-111.
45. Belmadani S., Bernal J., Wei C.C., Pallero M.A., Dell'italia L., Murphy-Ullrich J.E., et al. A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II. Am. J. Pathol. 2007, 171:777-789.
46. Xia Y., Dobaczewski M., Gonzalez-Quesada C., Chen W., Biernacka A., Li N., et al. Endogenous thrombospondin 1 protects the pressure-overloaded myocardium by modulating fibroblast phenotype and matrix metabolism. Hypertension 2011, 58:902-911.
47. Leung L.L., Nachman R.L. Complex formation of platelet thrombospondin with fibrinogen. J. Clin. Invest. 1982, 70:542-549.
48. Mumby S.M., Raugi G.J., Bornstein P. Interactions of thrombospondin with extracellular matrix proteins: selective binding to type V collagen. J. Cell Biol. 1984, 98:646-652.
49. Bale M.D., Mosher D.F. Effects of thrombospondin on fibrin polymerization and structure. J. Biol. Chem. 1986, 261:862-868.
50. Gonzalez-Quesada C., Cavalera M., Biernacka A., Kong P., Lee D.W., Saxena A., et al. Thrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiopoietin-2 upregulation. Circ. Res. 2013, 113:1331-1344.
51. Ma Y., Yabluchanskiy A., Lindsey M.L. Thrombospondin-1: the good, the bad, and the complicated. Circ. Res. 2013, 113:1272-1274.
52. Bein K., Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J. Biol. Chem. 2000, 275:32167-32173.
53. Yang Z., Kyriakides T.R., Bornstein P. Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2. Mol. Biol. Cell 2000, 11:3353-3364.
54. Emonard H., Bellon G., Troeberg L., Berton A., Robinet A., Henriet P., et al. Low density lipoprotein receptor-related protein mediates endocytic clearance of pro-MMP-2.TIMP-2 complex through a thrombospondin-independent mechanism. J. Biol. Chem. 2004, 279:54944-54951.
55. Yabluchanskiy A., Ma Y., Iyer R.P., Hall M.E., Lindsey M.L. Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology (Bethesda) 2013, 28:391-403.
56. Ramos-DeSimone N., Hahn-Dantona E., Sipley J., Nagase H., French D.L., Quigley J.P. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 1999, 274:13066-13076.
57. Hall M.C., Young D.A., Waters J.G., Rowan A.D., Chantry A., Edwards D.R., et al. The comparative role of activator protein 1 and smad factors in the regulation of timp-1 and MMP-1 gene expression by transforming growth factor-beta 1. J. Biol. Chem. 2003, 278:10304-10313.
58. Narouz-Ott L., Maurer P., Nitsche D.P., Smyth N., Paulsson M. Thrombospondin-4 binds specifically to both collagenous and non-collagenous extracellular matrix proteins via its C-terminal domains. J. Biol. Chem. 2000, 275:37110-37117.
59. Mustonen E., Ruskoaho H., Rysa J. Thrombospondin-4, tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14: novel extracellular matrix modulating factors in cardiac remodelling. Ann. Med. 2012, 44:793-804.
60. Sawaki D., Hou L., Tomida S., Sun J., Zhan H., Aizawa K., et al. Modulation of cardiac fibrosis by Kruppel-like factor 6 through transcriptional control of thrombospondin 4 in cardiomyocytes. Cardiovasc. Res. 2015, 107:420-430.
61. Dawson D.W., Volpert O.V., Pearce S.F., Schneider A.J., Silverstein R.L., Henkin J., et al. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol. Pharmacol. 1999, 55:332-338.
62. Dawson D.W., Pearce S.F., Zhong R., Silverstein R.L., Frazier W.A., Bouck N.P. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 1997, 138:707-717.
63. Asch A.S., Silbiger S., Heimer E., Nachman R.L. Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding. Biochem. Biophys. Res. Commun. 1992, 182:1208-1217.
64. Jimenez B., Volpert O.V., Reiher F., Chang L., Munoz A., Karin M., et al. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1. Oncogene 2001, 20:3443-3448.
65. Jimenez B., Volpert O.V., Crawford S.E., Febbraio M., Silverstein R.L., Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. 2000, 6:41-48.
66. Simantov R., Febbraio M., Silverstein R.L. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol. 2005, 24:27-34.
67. Yee K.O., Connolly C.M., Duquette M., Kazerounian S., Washington R., Lawler J. The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res. Treat. 2009, 114:85-96.
68. Iruela-Arispe M.L., Lombardo M., Krutzsch H.C., Lawler J., Roberts D.D. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 1999, 100:1423-1431.
69. Frieda S., Pearce A., Wu J., Silverstein R.L. Recombinant GST/CD36 fusion proteins define a thrombospondin binding domain. Evidence for a single calcium-dependent binding site on CD36. J. Biol. Chem. 1995, 270:2981-2986.
70. Primo L., Ferrandi C., Roca C., Marchio S., di Blasio L., Alessio M., et al. Identification of CD36 molecular features required for its in vitro angiostatic activity. FASEB J. 2005, 19:1713-1715.
71. Volpert O.V., Zaichuk T., Zhou W., Reiher F., Ferguson T.A., Stuart P.M., et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat. Med. 2002, 8:349-357.
72. Oganesian A., Armstrong L.C., Migliorini M.M., Strickland D.K., Bornstein P. Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol. Biol. Cell 2008, 19:563-571.
73. Henkin J., Volpert O.V. Therapies using anti-angiogenic peptide mimetics of thrombospondin-1. Expert Opin. Ther. Targets 2011, 15:1369-1386.
74. Cursiefen C., Masli S., Ng T.F., Dana M.R., Bornstein P., Lawler J., et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest. Ophthalmol. Vis. Sci. 2004, 45:1117-1124.
75. Rodriguez-Manzaneque J.C., Lane T.F., Ortega M.A., Hynes R.O., Lawler J., Iruela-Arispe M.L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12485-12490.
76. Maclauchlan S., Skokos E.A., Agah A., Zeng J., Tian W., Davidson J.M., et al. Enhanced angiogenesis and reduced contraction in thrombospondin-2-null wounds is associated with increased levels of matrix metalloproteinases-2 and -9, and soluble VEGF. J. Histochem. Cytochem. 2009, 57:301-313.
77. Agah A., Kyriakides T.R., Bornstein P. Proteolysis of cell-surface tissue transglutaminase by matrix metalloproteinase-2 contributes to the adhesive defect and matrix abnormalities in thrombospondin-2-null fibroblasts and mice. Am. J. Pathol. 2005, 167:81-88.
78. Muppala S., Frolova E., Xiao R., Krukovets I., Yoon S., Hoppe G., et al. Proangiogenic properties of thrombospondin-4. Arterioscler. Thromb. Vasc. Biol. 2015, 35:1975-1986.
79. Fernandez-Patron C., Shen M., Zhang P., Kassiri Z. ADAMs family and relatives in cardiovascular physiology and pathology. J. Mol. Cell. Cardiol. 2015, (in press, JMC9496).
80. Reilly M.P., Li M., He J., Ferguson J.F., Stylianou I.M., Mehta N.N., et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 2011, 377:383-392.
81. Wang L., Zheng J., Bai X., Liu B., Liu C.J., Xu Q., et al. ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries. Circ. Res. 2009, 104:688-698.
82. Kessler T., Zhang L., Liu Z., Yin X., Huang Y., Wang Y., et al. ADAMTS-7 inhibits re-endothelialization of injured arteries and promotes vascular remodeling through cleavage of thrombospondin-1. Circulation 2015, 131:1191-1201.
83. Lee N.V., Sato M., Annis D.S., Loo J.A., Wu L., Mosher D.F., et al. ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J. 2006, 25:5270-5283.
84. Iruela-Arispe M.L. Regulation of thrombospondin1 by extracellular proteases. Curr. Drug Targets 2008, 9:863-868.
85. Mustonen E., Aro J., Puhakka J., Ilves M., Soini Y., Leskinen H., et al. Thrombospondin-4 expression is rapidly upregulated by cardiac overload. Biochem. Biophys. Res. Commun. 2008, 373:186-191.
86. Zhang X.M., Shen F., Xv Z.Y., Yan Z.Y., Han S. Expression changes of thrombospondin-1 and neuropeptide Y in myocardium of STZ-induced rats. Int. J. Cardiol. 2005, 105:192-197.
87. Rysa J., Leskinen H., Ilves M., Ruskoaho H. Distinct upregulation of extracellular matrix genes in transition from hypertrophy to hypertensive heart failure. Hypertension 2005, 45:927-933.
88. Melenovsky V., Benes J., Skaroupkova P., Sedmera D., Strnad H., Kolar M., et al. Metabolic characterization of volume overload heart failure due to aorto-caval fistula in rats. Mol. Cell. Biochem. 2011, 354:83-96.
89. Swinnen M., Vanhoutte D., Van Almen G.C., Hamdani N., Schellings M.W., D'Hooge J., et al. Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation 2009, 120:1585-1597.
90. Lynch J.M., Maillet M., Vanhoutte D., Schloemer A., Sargent M.A., Blair N.S., et al. A thrombospondin-dependent pathway for a protective ER stress response. Cell 2012, 149:1257-1268.
91. van Almen G.C., Swinnen M., Carai P., Verhesen W., Cleutjens J.P., D'Hooge J., et al. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy. J. Mol. Cell. Cardiol. 2011, 51:318-328.
92. Lee D.I., Yu S.S., Bedja D., Kass D.A., Cingolani O.H. Abstract 20471: thrombospondin-4 is a key mediator in cardiac aging. Circ. 2014, 130:A20471.
93. Udelson J.E. Ventricular remodeling in heart failure and the effect of beta-blockade. Am. J. Cardiol. 2004, 93:43B-48B.
94. Babick A., Elimban V., Zieroth S., Dhalla N.S. Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction. J. Cell. Physiol. 2013, 228:2063-2070.
95. Mustonen E., Leskinen H., Aro J., Luodonpaa M., Vuolteenaho O., Ruskoaho H., et al. Metoprolol treatment lowers thrombospondin-4 expression in rats with myocardial infarction and left ventricular hypertrophy. Basic Clin. Pharmacol. Toxicol. 2010, 107:709-717.
96. van Almen G.C., Verhesen W., van Leeuwen R.E., van de Vrie M., Eurlings C., Schellings M.W., et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell. 2011, 10:769-779.
97. Cingolani O.H., Kirk J.A., Seo K., Koitabashi N., Lee D.I., Ramirez-Correa G., et al. Thrombospondin-4 is required for stretch-mediated contractility augmentation in cardiac muscle. Circ. Res. 2011, 109:1410-1414.
98. Von Anrep G. On the part played by the suprarenals in the normal vascular reactions of the body. J. Physiol. 1912, 45:307-317.
99. Caldiz C.I., Garciarena C.D., Dulce R.A., Novaretto L.P., Yeves A.M., Ennis I.L., et al. Mitochondrial reactive oxygen species activate the slow force response to stretch in feline myocardium. J. Physiol. 2007, 584:895-905.
100. 2+ release in cardiomyocytes. Nat. Cell Biol. 2001, 3:867-873.
101. Allen D.G., Kurihara S. The effects of muscle length on intracellular calcium transients in mammalian cardiac muscle. J. Physiol. 1982, 327:79-94.
102. Groenendyk J., Sreenivasaiah P.K. Kim do H, agellon LB, michalak M. Biology of endoplasmic reticulum stress in the heart. Circ. Res. 2010, 107:1185-1197.
103. Toth A., Nickson P., Mandl A., Bannister M.L., Toth K., Erhardt P. Endoplasmic reticulum stress as a novel therapeutic target in heart diseases. Cardiovasc. Hematol. Disord. Drug Targets 2007, 7:205-218.
104. Rainer P.P., Hao S., Vanhoutte D., Lee D.I., Koitabashi N., Molkentin J.D., et al. Cardiomyocyte-specific transforming growth factor beta suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction. Circ. Res. 2014, 114:1246-1257.
105. Ashokkumar M., Anbarasan C., Saibabu R., Kuram S., Raman S.C., Cherian K.M. An association study of thrombospondin 1 and 2 SNPs with coronary artery disease and myocardial infarction among south indians. Thromb. Res. 2011, 128:e49-e53.
106. Cui J., Randell E., Renouf J., Sun G., Green R., Han F.Y., et al. Thrombospondin-4 1186G>C (A387P) is a sex-dependent risk factor for myocardial infarction: a large replication study with increased sample size from the same population. Am. Heart J. 2006, 152:543 e1-5.
107. Cui J., Randell E., Renouf J., Sun G., Han F.Y., Younghusband B., et al. Gender dependent association of thrombospondin-4 A387P polymorphism with myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 2004, 24:e183-e184.
108. Gao L., He G.P., Dai J., Ma J.Z., Yang G.Y., Qi C.P., et al. Association of thrombospondin-1 gene polymorphisms with myocardial infarction in a Chinese Han population. Chin. Med. J. 2008, 121:78-81.
109. Koch W., Hoppmann P., de Waha A., Schomig A., Kastrati A. Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence. Hum. Mol. Genet. 2008, 17:1120-1126.
110. Vila V., Martinez-Sales V., Almenar L., Lazaro I.S., Villa P., Reganon E. Inflammation, endothelial dysfunction and angiogenesis markers in chronic heart failure patients. Int. J. Cardiol. 2008, 130:276-277.
111. Batlle M., Perez-Villa F., Lazaro A., Garcia-Pras E., Vallejos I., Sionis A., et al. Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling. Transplant. Proc. 2009, 41:2231-2233.
112. Kimura Y., Izumiya Y., Hanatani S., Yamamoto E., Kusaka H., Tokitsu T., et al. High serum levels of thrombospondin-2 correlate with poor prognosis of patients with heart failure with preserved ejection fraction. Heart Vessel. 2014.
113. Vila V., Sales V.M., Almenar L., Lazaro I.S., Villa P., Reganon E. Effect of oral anticoagulant therapy on thrombospondin-1 and von willebrand factor in patients with stable heart failure. Thromb. Res. 2008, 121:611-615.
114. Tan F.L., Moravec C.S., Li J., Apperson-Hansen C., McCarthy P.M., Young J.B., et al. The gene expression fingerprint of human heart failure. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:11387-11392.
115. Adolph K.W. Relative abundance of thrombospondin 2 and thrombospondin 3 mRNAs in human tissues. Biochem. Biophys. Res. Commun. 1999, 258:792-796.
116. Lindsey M.L., Iyer R.P., Zamilpa R., Yabluchanskiy A., DeLeon-Pennell K.Y., Hall M.E., et al. A novel collagen matricryptin reduces left ventricular dilation post-myocardial infarction by promoting scar formation and angiogenesis. J. Am. Coll. Cardiol. 2015, 66:1364-1374.
117. Riessen R., Fenchel M., Chen H., Axel D.I., Karsch K.R., Lawler J. Cartilage oligomeric matrix protein (thrombospondin-5) is expressed by human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2001, 21:47-54.
118. Helkin A., Maier K.G., Gahtan V. Thrombospondin-1, -2 and -5 have differential effects on vascular smooth muscle cell physiology. Biochem. Biophys. Res. Commun. 2015, 464:1022-1027.